Companies sponsors |
AbbVie (risankizumab) |
Others |
Department of Health and Social Care |
|
NHS England |
Patient carer groups |
Crohn’s and Colitis UK |
Professional groups |
Royal College of Physicians |
|
UK Clinical Pharmacy Association |
Associated guideline groups |
NICE - National Guideline Centre |
Comparator companies |
Abbvie (adalimumab, upadacitinib) (CAU signed- participating) |
|
Amgen (adalimumab) (CAU not signed- not participating) |
|
Biogen Idec (adalimumab, infliximab) (CAU not signed- not participating) |
|
Bristol-Myers Squibb Pharmaceuticals (ozanimod) (CAU not signed- not participating) |
|
Celltrion Healthcare UK (adalimumab, infliximab) (CAU not signed- not participating) |
|
Eli Lilly and Company (mirikizumab) (CAU not signed- not participating) |
|
Frezenius Kabi (adalimumab) (CAU not signed- not participating) |
|
Galapagos Biotech (filgotinib) (CAU not signed- not participating) |
|
Janssen-Cilag (ustekinumab) (CAU signed- participating) |
|
Merck, Sharp and Dohme, UK (golimumab, infliximab) (CAU not signed- not participating) |
|
Pfizer (infliximab, tofacitinib, etrasimod) (CAU not signed- not participating) |
|
Sandoz (adalimumab, infliximab) (CAU not signed- not participating) |
|
Takeda UK (vedolizumab) (CAU signed- participating) |
Evidence review group |
National Institute for Health Research Health Technology Assessment Programme (NETSCC) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
Welsh Government |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
National Institute for Health Research |